Doctor's Notes

Does Childhood Eczema Lower Test Scores? A 3,641-Child Study Challenges Assumptions

AI-generated illustration: Dr. Arsy #003 on a teacher’s desk

Dr. Arsy Editorial Team · November 9, 2026

Itch and lost sleep can make a school day harder, so it may sound logical that childhood eczema lowers academic test performance. A longitudinal US birth-cohort analysis did not support that broad assumption. Among 3,641 children with analyzed data, eczema was associated with comparable or slightly higher results on several standardized measures.[1]

What researchers measured

Caregivers reported eczema symptoms when children were ages 5 and 9. Standardized tests assessed vocabulary, reading and mathematics. Adjusted models found a small positive association with vocabulary, no difference in reading at the same age, and no difference in math at age 9. Eczema at age 5 was associated with slightly higher reading at age 9.

Why this does not mean eczema improves learning

Observational associations cannot establish cause. The authors suggested sedentary activities such as reading might partly counterbalance distraction or sleep effects, but that is a hypothesis. Caregiver-reported eczema, residual socioeconomic differences, treatment, school support and unmeasured severity may influence results.

Population averages do not erase individual burden

A child with severe itch, bullying, anxiety or repeated sleep disruption may still need support even when average test scores are not lower. A separate two-country study asked related academic questions using different data and methods. The findings should be read together rather than reduced to one universal conclusion.[6][8][24]

What schools and families can track

  • Sleep loss and morning fatigue
  • Scratching or discomfort during class
  • Missed school and medical appointments
  • Difficulty concentrating during a flare
  • Needed access to a written care plan or school nurse

Support should respond to the child’s actual symptoms and participation, not a stereotype that eczema determines intelligence or academic potential.

Product context

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the research above and is not a substitute for medical assessment or prescription care. Ask a pediatric clinician before using a specific product on a baby.

Related pediatric eczema research

Research and clinical references

  1. Childhood atopic dermatitis and standardized testing: US birth cohort.
  2. PEDISTAD systemic treatment outcomes by skin color.
  3. PEDISTAD growth assessment in children under 12.
  4. TREATKids clinical and molecular outcomes with dupilumab.
  5. Tapinarof efficacy by race and Fitzpatrick skin type.
  6. Atopic dermatitis and academic performance in Denmark and England.
  7. Atopic dermatitis, sleep and cognition in US adults.
  8. Eczema and educational attainment: systematic review.
  9. Pediatric atopic dermatitis guideline.
  10. AAP skin-directed management clinical report.
  11. AAAAI/ACAAI atopic dermatitis guideline.
  12. Dupilumab in children 6 months to younger than 6 years.
  13. Dupilumab in children 6 to 11 years with severe atopic dermatitis.
  14. Dupilumab in adolescents with atopic dermatitis.
  15. Tapinarof ADORING phase 3 trials.
  16. Long-term topical therapy in pediatric atopic dermatitis: ROAD study.
  17. Atopic dermatitis and child height: systematic review.
  18. Growth and nutritional status in children with atopic dermatitis.
  19. Atopic dermatitis in skin of color: clinical considerations.
  20. Racial and ethnic representation in atopic dermatitis trials.
  21. Core outcome instruments for atopic eczema.
  22. EASI validation across skin types.
  23. Patient-Oriented Eczema Measure validation in children.
  24. Atopic dermatitis quality-of-life burden in children and families.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes